Why Did BSX, LI, ROL Stocks Fall To 52-Week Lows On Friday?

Analyst downgrades, weak outlooks, and management changes added pressure.
Employees adjust new energy vehicles at the workshop of Li Auto Changzhou Manufacturing Base on December 10, 2024 in Changzhou, Jiangsu Province of China. (Photo by Chen Wei/VCG via Getty Images)
Employees adjust new energy vehicles at the workshop of Li Auto Changzhou Manufacturing Base on December 10, 2024 in Changzhou, Jiangsu Province of China. (Photo by Chen Wei/VCG via Getty Images)
Profile Image
Shivani Kumaresan·Stocktwits
Published May 31, 2026   |   11:01 PM EDT
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...
  • Boston Scientific shares fell to a 52-week low of $48.13 and lost 16% for the week after weaker expectations for its Watchman device business. 
  • Li Auto came under pressure after reporting weaker profitability, prompting Barclays to cut its price target to $14 from $18. 
  • Bernstein downgraded Rollins and cut its price target to $52 from $70, citing concerns that CFO Ken Krause’s departure could slow profitability improvements. 

Boston Scientific Corp. (BSX), Li Auto Inc. (LI), and Rollins Inc. (ROL) each dropped to new 52-week lows on Friday as investor sentiment toward premium-priced growth stocks took a hit. 

Concerns surrounding product growth, earnings prospects, and valuation levels weighed on the three companies. While Li Auto and Rollins stocks declined over 3% each, Boston Scientific stock ended Friday’s session over 1% lower. 

Read Next
Loading...
Loading...

BSX Faces Growth Questions

Boston Scientific stock hit a 52-week low of $48.13, enduring a 16% weekly decline on weaker expectations for the company's Watchman heart-device franchise. 

Management's indication that U.S. Watchman revenue could remain weak through the next two quarters raised doubts about the pace of future expansion and prompted analysts to lower price targets.

On Friday, both Wolfe Research and TD Cowen adjusted their views on the company. Wolfe Research downgraded Boston Scientific to ‘Peer Perform’ from ‘Outperform’. 

The firm revised its financial projections after incorporating management's updated outlook for the Watchman device business. Analysts now estimate organic revenue expansion of roughly 7% in 2027, a pace they believe supports a share valuation in the low-$50 range, close to where the stock currently trades.

TD Cowen lowered its price target to $61 from $80 and maintained its Buy rating on Boston Scientific. However, on Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory. 

LI Battles EV Industry Headwinds

Li Auto came under pressure after its first-quarter earnings report on Thursday showed weaker profits. The Chinese EV maker also forecast lower Q2 deliveries of 95,000 to 100,000 vehicles, pointing to softer demand and intense competition in China's price-cutting EV market. 

Li Auto posted Q1 revenue of RMB23 billion ($3.3 billion), representing an 11% decline from last year. The company recorded a net loss of RMB2.3 billion for the quarter, a sharp reversal from the RMB646.6 million net profit it generated last year.

Following the Q1 earnings report, Barclays lowered its price target on Li Auto to $14 from $18 while maintaining an ‘equal weight’ rating on the stock. The new price target implies nearly a 7% downside to the stock’s closing price on Friday. 

Retail sentiment around the stock turned to ‘bullish’ from ‘neutral’ territory the previous day. 

ROL Confronts Valuation Reset

Rollins reached a new yearly low of $46.85 despite reporting solid operating performance in April. Investors instead focused on valuation concerns, with some analysts arguing that the stock's premium pricing no longer aligns with its expected growth trajectory. 

The upcoming appointment of a new chief financial officer in mid-June added another variable for investors evaluating future performance.

On Friday, Bernstein analyst Connor Cerniglia downgraded Rollins to ‘Market Perform’ from ‘Outperform’ and lowered his price target to $52 from $70, citing concerns that the CFO departure could complicate efforts to improve profitability in the years ahead.

The analyst pointed to the departure of CFO Ken Krause, describing him as an important contributor to the company's efforts to enhance profitability and streamline operations.

Retail sentiment around the stock changed to ‘bullish’ from ‘extremely bullish’ the previous day. 

So far this year, while BSX and ROL stocks have declined by over 49% and  20% respectively, LI stock has shed over 11%. 

Also See: TMHC Stock Jumps Into Spotlight After Berkshire's Surprise $8.5B Housing Bet

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Follow on Google News
Read about our editorial guidelines and ethics policy